Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?

BENER, Abdülbari; ÖZTÜRK, Mustafa K.; ÇATAN, Funda

doi:10.14744/etd.2019.33230

Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?

Funda ÇATAN, (İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Biyoistatistik ve Tıp Bilişimi Anabilim Dalı, İstanbul, Türkiye)

Abdülbari BENER, (İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Biyoistatistik ve Tıp Bilişimi Anabilim Dalı, İstanbul, Türkiye)

Mustafa K. ÖZTÜRK (İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Rejeneratif ve Restoratif Tıp Araştırma Merkezi, İstanbul, Türkiye)

Erciyes Medical Journal

1 1

Yıl: 2020 Cilt: 42 Sayı: 1 Sayfa Aralığı: 71 - 77 Metin Dili: İngilizce DOI: 10.14744/etd.2019.33230 İndeks Tarihi: 26-11-2020

Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?

Öz:

Objective: The aim of this study was to determine the relationship between microvascular Type 2 diabetes mellitus (T2DM)complications and the severity and duration of diabetes in the light of sociodemographic and lifestyle variables.Materials and Methods: This is a prospective cohort study based on 899 (527 females, 372 males) patients with T2DMaged 25–70 years. Patient information including socio-demographic variables; body mass index (BMI); lifestyle habits andduration of diabetes; treatment of diabetes; values for hemoglobin A1c (HbA1c); development of diabetes complications; andthe presence of neuropathy, nephropathy, and retinopathy were recorded. A univariate and multivariate statistical analysiswere performed.Results: Significant differences were found between diabetics with HbA1c ≤7 and >7 in terms of the education level, occupation, household income, duration of diabetes, the number of children, smoking, physical exercise, eating fast food, controlregularity, and diabetes education. A total of 17.1% of patients had diabetic retinopathy, 17.0% had neuropathy, and 13.7%had nephropathy. Among diabetics, 2.3% had three microvascular complications, whereas 66.6% had none of them. Theprevalence of diabetes complications was lower in patients who had good glycemic control than those who had poor glycemiccontrol. Furthermore, the highest reduction in the level of HbA1c was for sulfonylurea usage.Conclusion: A high prevalence of diabetes complications is a burden for both the patients and the health care system.Screening, early diagnosis, management of the glucose level, and the follow-up may result in delayed diabetes complications.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. American Diabetes Association. Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42(Suppl 1): S1–2.
2. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103(2): 137–49.
3. International Diabetes Federation. Diabetes Atlas. 8th ed. Belgium; IDF: 2017.
4. Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, et al. Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes Care 2002; 25(9): 1551–6.
5. Süleymanlar G, Utaş C, Arinsoy T, Ateş K, Altun B, Altiparmak MR, et al. A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study. Nephrol Dial Transplant 2011; 26(6): 1862–71.
6. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, et al; TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28(2): 169–80.
7. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013; 93(1): 137–88.
8. Bener A, Al-Laftah F, Al-Hamaq AO, Daghash M, Abdullatef WK. A study of diabetes complications in an endogamous population: an emerging public health burden. Diabetes Metab Syndr 2014; 8(2): 108–14.
9. American Diabetes Association. Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42(Suppl 1): S66.
10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32(1): 193–203.
11. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE). Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm--2016 Executive Summary. Endocr Pract 2016; 22(1): 84–113.
12. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–53.
13. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 854–65.
14. Basit A, Hydrie MZ, Hakeem R, Ahmedani MY, Masood Q. Frequency of chronic complications of type II diabetes. J Coll Physicians Surg Pak 2004; 14(2): 79–83.
15. Bener A, Keskin FE, Kurtulus EM, Guzel M, Çekirdekçi EI, Kadıoğlu P, et al. Essential parameters and risk factors of the patients for diabetes care and treatment. Diabetes Metab Syndr 2017; 11 (Suppl 1): S315–20.
16. Field A. Discovering statistics using IBM SPSS statistics. 4th ed. London: Sage Publications; 2013.
17. Tabachnick BG, Fidell LS, Ullman JB. Using multivariate statistics. Boston, MA: Pearson; 2007.
18. Green SB, Salkind NJ. Using SPSS for Windows and Macintosh, books a la carte. 8th ed. London: Pearson; 2016.
19. Bircan H. Lojistik regresyon analizi: Tıp verileri üzerine bir uygulama. Kocaeli Üniversitesi Sosyal Bilimler Dergisi 2004; 2(8):185–208.
20. Liu Z, Fu C, Wang W, Xu B. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes 2010; 8: 62.
21. Bener A, Al-Hamaq AOAA, Çatan F, Rajput KU, Guzel M. Gender Satisfaction among Type 2 Diabetes Patients: A Comparison between Intensive Diets, Lifestyle Intervention with Medication Controlled Management. BJMMR 2016; 18(7): 1–13.
22. Madmoli M, Mahmoudi Dehcheshmeh Z, Rafi A, Kord Z, Mobarez F, et al. The rate of some complications and risk factors of diabetes in diabetic patients: Study on cases of 3218 diabetic patients. Medical Science 2019; 23(95): 63–8.
23. Yokoyama H, Oishi M, Takamura H, Yamasaki K, Shirabe SI, Uchida D, et al. Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes (JDDM 40). BMJ Open Diabetes Res Care 2016; 4(1): e000294.
24. Harzallah F, Ncibi N, Alberti H, Ben Brahim A, Smadhi H, Kanoun F, et al. Clinical and metabolic characteristics of newly diagnosed diabetes patients: experience of a university hospital in Tunis. Diabetes Metab 2006; 32(6): 632–5.
25. Bruce SG, Young TK. Prevalence and risk factors for neuropathy in a Canadian First Nation community. Diabetes Care 2008; 31(9): 1837– 41.
26. Magee GM, Hunter SJ, Cardwell CR, Savage G, Kee F, Murphy MC, et al. Identifying additional patients with diabetic nephropathy using the UK primary care initiative. Diabet Med 2010; 27(12): 1372–8.
27. Otieno CF, Kariuki M, Ng’ang’a L. Quality of glycaemic control in ambulatory diabetics at the out-patient clinic of Kenyatta National Hospital, Nairobi. East Afr Med J 2003; 80(8): 406–10.
28. Ağırman E, Marangoz B, Gençer MZ, Arıca S, Zegerek K. The Relationship between Oran Anti Diabetic Drugs with HbA1c, Obesity and Complications in Type 2 Diabetic Patients. Balıkesir Med J 2018; 2(2): 93–01.
29. Fereidony M, Shoghiyan-davar M, Bigane OB, Bashiri Y, DehghaniArani M, et al. Investigating Factors Associated with Diabetes Complications among Type 2 Diabetic Patients. J Res Med Dent Sci 2018; 6(3): 301–6.
30. Aiello LP; DCCT/EDIC Research Group. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/ epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37(1): 17–23.
31. Çelik S, İdiz C, Bağdemir E, Purisa S, Dinççağ N, et al. Comparison of Self-Monitoring Blood Glucose with HbA1c and Diabetes Complications in Diabetics. J Nutrition Dietetics 2018; 46(2): 118–24.
32. St Onge EL, Miller S, Clements E. Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus. PT 2012; 37(12): 699–708.
33. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013; 56(5): 973–84.
34. Flory JH, Small DS, Cassano PA, Brillon DJ, Mushlin AI, Hennessy S. Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin. J Comp Eff Res 2014; 3(1): 29–39.

APA	ÇATAN F, BENER A, ÖZTÜRK M (2020). Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?. , 71 - 77. 10.14744/etd.2019.33230
Chicago	ÇATAN Funda,BENER Abdülbari,ÖZTÜRK Mustafa K. Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?. (2020): 71 - 77. 10.14744/etd.2019.33230
MLA	ÇATAN Funda,BENER Abdülbari,ÖZTÜRK Mustafa K. Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?. , 2020, ss.71 - 77. 10.14744/etd.2019.33230
AMA	ÇATAN F,BENER A,ÖZTÜRK M Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?. . 2020; 71 - 77. 10.14744/etd.2019.33230
Vancouver	ÇATAN F,BENER A,ÖZTÜRK M Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?. . 2020; 71 - 77. 10.14744/etd.2019.33230
IEEE	ÇATAN F,BENER A,ÖZTÜRK M "Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?." , ss.71 - 77, 2020. 10.14744/etd.2019.33230
ISNAD	ÇATAN, Funda vd. "Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?". (2020), 71-77. https://doi.org/10.14744/etd.2019.33230

APA	ÇATAN F, BENER A, ÖZTÜRK M (2020). Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?. Erciyes Medical Journal, 42(1), 71 - 77. 10.14744/etd.2019.33230
Chicago	ÇATAN Funda,BENER Abdülbari,ÖZTÜRK Mustafa K. Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?. Erciyes Medical Journal 42, no.1 (2020): 71 - 77. 10.14744/etd.2019.33230
MLA	ÇATAN Funda,BENER Abdülbari,ÖZTÜRK Mustafa K. Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?. Erciyes Medical Journal, vol.42, no.1, 2020, ss.71 - 77. 10.14744/etd.2019.33230
AMA	ÇATAN F,BENER A,ÖZTÜRK M Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?. Erciyes Medical Journal. 2020; 42(1): 71 - 77. 10.14744/etd.2019.33230
Vancouver	ÇATAN F,BENER A,ÖZTÜRK M Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?. Erciyes Medical Journal. 2020; 42(1): 71 - 77. 10.14744/etd.2019.33230
IEEE	ÇATAN F,BENER A,ÖZTÜRK M "Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?." Erciyes Medical Journal, 42, ss.71 - 77, 2020. 10.14744/etd.2019.33230
ISNAD	ÇATAN, Funda vd. "Is There a Relationship Between Microvascular Complications and the Severity of Type 2 Diabetes Mellitus?". Erciyes Medical Journal 42/1 (2020), 71-77. https://doi.org/10.14744/etd.2019.33230